Biogen Idec Inc.
14 Cambridge Center
Cambridge,
MA 02142
United States - Map
Phone: 617-679-2000
Fax: 617-679-2617
Web Site: http://www.idecpharm.com
| Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally. The companys marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkins Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Anti-CD80 MAb, a Phase III clinical trial product for the treatment of relapsed NHL; Anti-CD23 MAb, a Phase II/III clinical trial product for the treatment of relapsed or refractory chronic lymphocytic leukemia; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Acute Hyponatremia; and ADENTRI, a Phase III clinical trial product for acute decompensated heart failure patients with renal insufficiency. The companys products under preclinical stage comprise BIIB014, Daclizumab, CDP323, Humanized Anti-CD20 MAb, PEG-IFN beta 1a, Neublastin, and LINGO for neurology; Volociximab, Hsp90 Inhibitor, GA101, Anti-IGF-1R, Anti-CRIPTO, RAF Inhibitor, and Anti-Fn14 for oncology; BG-12, Anti-TWEAK, Anti-CD40L Fab, and Anti-FcRn for autoimmune and inflammatory diseases; and ADENTRI and Aviptadil for cardiovascular diseases. It has collaboration agreements with Neurimmune SubOne AG; Cardiokine Biopharma LLC; mondoBIOTECH, AG; Alnylam Pharmaceuticals, Inc.; UCB, S.A.; Facet Biotech Corporation; Sunesis Pharmaceuticals, Inc.; Vernalis plc; Vetter Pharma-Fertigung GmbH & Co. KG; and Schering AG, as well as a definitive agreement with AVEO Pharmaceuticals Inc. The company was founded in 1985 and is based in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. James C. Mullen , 50
Chief Exec. Officer, Pres |
$
3.59M |
$
17.81M | Dr. Phillip A. Sharp Ph.D., 64
Co-Founder |
$
77.00K | N/A | Mr. Paul J. Clancy , 47
Chief Financial Officer and Exec. VP of Fin. |
$
1.64M |
$
0 | Mr. Robert Hamm M.A., 57
Chief Operating Officer and Exec. VP of Pharmaceutical Operations & Technology |
$
1.55M |
$
2.77M | Mr. John M. Dunn J.D., 56
Exec. VP of New Ventures |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.29% Nasdaq 
Profile
